Università di Perugia-ko ikertzaileekin lankidetzan egindako argitalpenak (38)

2023

  1. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  2. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

    Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70

  3. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  4. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 112, pp. 29-36

  5. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

    American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868

2022

  1. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807

  2. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847

  3. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  4. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

    European Journal of Cancer, Vol. 165, pp. 136-145

  5. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

    The Lancet, Vol. 399, Núm. 10333, pp. 1383-1390

  6. Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need

    Thrombosis Update, Vol. 6

2021

  1. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

    Leukemia, Vol. 35, Núm. 12, pp. 3444-3454

  2. Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451

    Annals of oncology : official journal of the European Society for Medical Oncology

  3. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Cancer, Vol. 148, pp. 371-381

  4. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    Annals of Oncology, Vol. 32, Núm. 4, pp. 439-451

  5. Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 8, pp. 1609-1622

  6. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1900-1907

  7. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Apixaban for the treatment of venous thromboembolism associated with cancer

    New England Journal of Medicine, Vol. 382, Núm. 17, pp. 1599-1607

  2. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

    Leukemia, Vol. 34, Núm. 9, pp. 2354-2363